Corrective information regarding the Annual Report 2024 and the Interim Report for H1 2025 following an order from the Danish Business Authority

Core Viewpoint - The company, Pharma Equity Group A/S, is correcting its Annual Report for 2024 and Interim Report for H1 2025 following an order from the Danish Business Authority to apply an "Expected Credit Loss" (ECL) model for measuring receivables from Portinho S.A. [2][5] Summary by Sections Financial Consequences - The carrying amount of the receivable from Portinho S.A. as of December 31, 2024, is reduced from TDKK 58,000 to TDKK 41,812, resulting in a correction of TDKK 16,188 recognized in the income statement for 2024 [5][8] - For H1 2025, the fair value of the receivable is reassessed at TDKK 33,697, leading to a total negative correction of TDKK 24,303 in the balance sheet [9][10][14] Income Statement Adjustments - The operating profit/loss (EBIT) for 2024 remains at -21,287 TDKK, while the profit/loss for the year is adjusted from -24,422 TDKK to -40,610 TDKK due to the allowance for the Portinho receivable [8] - For H1 2025, the profit/loss for the year is adjusted from -9,495 TDKK to -17,610 TDKK, reflecting the correction of the allowance for the Portinho receivable [14] Auditor's Review and Future Steps - The company's auditor, BDO Statsautoriseret Revisionsaktieselskab, is reviewing the corrective information and will issue an auditor's report within approximately 14 days [3] - The company maintains its legal claim against the debtor and continues to pursue recovery through ongoing negotiations [11]